Group items tagged

The National Health Service England (NHSE) aims to eliminate cervical cancer by 2040 by making the lifesaving Human Papillomavirus (HPV) vaccination easily accessible to people and increasing cervical screening uptake. In addition to the campaign, the NHS is expanding the outreach of cervical screening more than ever before. Last year, the health service invited over five million people aged 25 to 64 for the screening, out of which 3.5 million were tested. Moreover, self-sampling will be trialled to see if the service can introduced as part of national screening. England is among the first countries in the world to set this elimination ambition, which could save thousands of lives every year in the country. Amanda Pritchard, chief executive of Officer of NHS England, announced the health service's new goal and how to achieve it at the NHS Providers' annual conference today (15 November).

Pharma giant, Pfizer has announced plans to cut 500 jobs at its Sandwich site in Kent, England as part of its ongoing $3.5 billion cost-cutting drive. The company is also planning to shut its Pharmaceutical Sciences Small Molecule (PSSM) capabilities at the site, a spokesperson of the company told FiercePharma. However, the Sandwich site will remain open and other functions will continue with "a different size," the spokesperson added. Currently, around 940 people are employed at the site, which is the location where Pfizer scientists first discovered Viagra. "We are proud of our heritage of breakthrough science in the UK and we will retain a scientific presence in the U.K. including at our Discovery Park location in Sandwich," Pfizer's spokesperson confirmed in an email to FiercePharma.

NHS England is rolling out a range of tech and data solutions, including an artificial intelligence (AI) system, across the health service to tackle winter pressures. The AI system will be used to identify patients at risk of hospital admission so community NHS teams can get to them first and reduce pressures on A&E departments. On a trial basis, four GP practices in Somerset have started using the innovative technology which can highlight registered patients with complex health needs. Health coaches, nurses, or GPs will then reach out to the people most at risk, and provide them with a range of preventive care such as monitoring, food parcels, cleaning, shopping, as well as escalating care to specialist doctors.

Travelling with medical cannabis can be a complex and often confusing experience, given the diverse legal regulations across different countries and states. Patients who rely on medical cannabis for their wellbeing need to be well-informed and prepared to ensure a smooth and hassle-free travel experience. This comprehensive guide covers essential aspects, legal considerations, and practical tips for individuals who use medical cannabis and wish to travel. Know the Laws The first and most crucial step before travelling with medical cannabis is to understand the laws and regulations of both the departure and destination locations. Laws regarding medical cannabis use vary significantly from one country, state, or even city to another. Some places have legalised medical cannabis, while others strictly prohibit its use. Researching and familiarising oneself with the specific regulations of the destination, transit countries, and the home country is essential. Travelling Within the Same Country When travelling within a country where medical cannabis is legal, patients generally need to carry their prescription information issued by a licensed healthcare provider. It's advisable to keep medical cannabis in its original packaging, clearly labelled with the patient's name, prescribing physician, and dosage instructions. Carrying a copy of the relevant laws and regulations can also be helpful in case of any inquiries from authorities. What can be easier than carrying around paperwork, which could get easily damaged or lost during your travels, is to get a medical card that has a unique QR code on it from Releaf Cannabis, which, when scanned, can present their prescription information digitally - it has revolutionised the way patients manage their healthcare. This eliminates the need for physical documents and streamlines the process but also ensures the security and confidentiality of sensitive medical information, offering patients a more efficient and organi

How does your physician perform costochondritis treatment? First things first, Costochondritis is the inflammation of your rib cage i.e. bone/cartilage connecting the ribs to the sternum (breastbone), and can be a source of significant discomfort as I have clearly defined in the costochondritis symptoms section. Costochondritis is one of the most common causes of breast pain in ladies. Here In this guide, I will delve deeper into the various treatment options and approaches to manage costochondritis, considering a wide range of methods that reflect the diverse ways you can seek relief and healing.

Cancer patients in the UK are being given a new immunotherapy treatment at Imperial College Healthcare NHS Trust as part of a global phase 1/2 clinical trial, which aims to evaluate its safety and potential for treating 'solid tumour' cancers such as melanoma and lung cancer. The experimental therapy, called mRNA-4359, has been designed to train patients' immune systems to recognise and fight cancer cells, according to researchers at Imperial College London. For the first time in the UK, cancer patients received the treatment at the National Institute for Health and Care Research (NIHR) Imperial Clinical Research Facility at Hammersmith Hospital. In this non-randomised trial, mRNA-4359 is administered to patients either alone or in combination with an existing cancer drug called pembrolizumab, a type of immune checkpoint inhibitor. The researchers are hopeful that this new therapeutic approach, if proven to be safe and effective in clinical trials, could lead to a new treatment option for difficult-to-treat cancers.

Global healthcare company Mundipharma and Vectura, an inhalation contract development and manufacturing organization, have entered into a collaboration agreement aimed at reformulating an asthma inhaler as part of their commitment to reducing the product's carbon footprint. The companies will be working together on incorporating an environmentally friendly propellant into the formulation of flutiform, a pressurised metered-dose inhaler (pMDI) used for asthma treatment, to achieve a near-zero-emissions product. Currently, the product uses the approved apaflurane hydrofluoroalkane 227 (HFA-227), a type of fluorinated greenhouse gas, as its propellant. The European Union's regulation on these types of greenhouse gases targets a two-thirds reduction in their usage and subsequent emissions by 2030. In a joint statement, companies revealed that work is already in progress to find an alternative to the HFA-227 gas. Yuri Martina, Chief Development and Medical Officer at Mundipharma, said: "This is the first step in our long-term plan to develop a near-zero-emissions asthma inhaler.

In the next 10 years, the incidence of first-time stroke cases in the UK is projected to increase by 60 per cent, costing the government £75bn in healthcare and lost productivity, a charity has suggested. A new manifesto published by the Stroke Association has urged the next UK government to make stroke "the priority", stressing that the next decade is crucial for stroke prevention, treatment and recovery. Currently, stroke is the UK's fourth biggest killer and a leading cause of disability. On a daily basis, 281 individuals experience a stroke. Next year, the cost of stroke in the UK will be £43 billion. The charity predicted that by 2035, there will be 151,000 hospital admissions due to stroke every year, averaging 414 admissions per day, with 42,000 people estimated to die every year. In 2035, the UK is projected to have 2.1 million stroke survivors, imposing a financial burden of £75 billion on the public purse, nearly half the current NHS budget.

The UK government's community diagnostic centre programme, which was first launch in July 2021, is helping cut waiting lists, and speed up diagnoses and treatments for NHS patients. As of November 2023, a total of 6.1 million vital checks have been carried out at community diagnostic centres (CDCs) across England, according to a joint statement released by the Department of Health and Social Care (DHSC) and NHS England. Under the £2.3 billion programme, 141 CDCs have been opened across the country in a variety of settings including shopping centres, university campuses and football stadiums, offering patients a wide range of diagnostic tests closer to home. The government has set a target to open 160 CDCs by March 2025, with many expected to open ahead of schedule.

The topic of death is often a sensitive and somber one, but it is also a reality that we must face. When someone passes away, there are many legal considerations that come into play surrounding their assets, property, and final wishes. Before delving into the specifics, you must first understand that laws and regulations surrounding death and inheritance can vary greatly depending on location. Different countries, states, and even cities may have their own unique set of laws and procedures in place. involved. That's why you need a legal overview to guide you through the process of protecting your rights in the case of death. Wrongful Death Lawsuits and Compensation In the unfortunate event of a wrongful death, where a person dies due to the negligence or misconduct of another, the bereaved family may seek compensation through legal action. Hiring a lawyer for wrongful death is the best course of action to navigate the complex legal process and ensure that your rights are protected. Wrongful death lawsuits can cover a wide range of incidents, from car accidents to medical malpractice. The compensation awarded in these cases may include funeral expenses, lost wages, and loss of companionship. Know that each case is unique and the amount of compensation awarded will depend on the deceased's income and potential earnings, their age, and the extent of their financial support to their dependents.

The UK government on Thursday (8 May) launched a new plan to tackle antimicrobial resistance (AMR), a global issue that makes infections difficult or impossible to treat. This is the second phase of a series of 5-year national action plans, aimed at supporting the government's 20-year vision to contain and control AMR by 2040. With the launch of this new national action plan, the UK commits to reducing its use of antimicrobials - such as antibiotics, antifungals and antivirals - in humans and animals. Additionally, it aims to strengthen surveillance of drug-resistant infections before they emerge and incentivise industry to develop the next generation of treatments. There are also plans to expand initiatives such as the world-first 'subscription model' for antimicrobials, launched in 2019 as a pilot.

In a recent announcement, King Charles has agreed to become a patron of the society at Royal Pharmaceutical Society (RPS) following the footsteps of the late Queen. Buckingham Palace confirmed the news, marking the first anniversary of the Coronation of His Majesty The King and Her Majesty The Queen. This prestigious appointment comes after a meticulous evaluation of over 1000 Patronages, previously held by The late Queen, The former Prince of Wales, and The former Duchess of Cornwall. The decision underscores His Majesty's commitment to supporting organisations dedicated to advancing healthcare and patient well-being. The RPS has a rich history of association with the Royal Family, notably with The late Queen, who served as patron from 1953 until her passing in 2022.

American pharmaceutical giant Pfizer has received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) for its medication Etrasimod, marketed as Velsipity, used to treat people with moderately to severely active ulcerative colitis. Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD) that causes inflammation and ulcers (sores) in the lining of the large intestine (colon) and rectum. The approved recommended dose for Velsipity is one 2 mg tablet to be taken once daily. For the first three days, it is advised to take the medication with food, and subsequently, it can be taken daily either with or without food. According to the regulator, the approval of the medication is based on evidence from two clinical studies, which showed that 26 per cent of patients taking etrasimod achieved clinical remission after 12 weeks of treatment compared with 11 per cent of those receiving placebo. The studies included more than 740 patients aged 16 years and over for whom standard treatment or other treatments did not work well enough or could not be used.

Kamila Hawthorne, the chair of the Royal College of General Practitioners (RCGP) Council, was honoured with the GG2 Woman of the Year Award at the annual GG2 Leadership and Diversity Awards, held at the Park Plaza Hotel on Tuesday, 5 March. Hawthorne has been a practitioner and a mentor to young GPs for almost 35 years, and has led pioneering research projects focusing on health inequalities, diabetes and heart disease. She has been recognised twice as GP of the Year for her work with minority ethnic communities. Professor Kiran Patel, Group Chief Medical Officer at University Hospitals Birmingham NHS Foundation Trust, was named the GG2 Man of the Year Award. Apart from being a sought-after cardiologist and consultant, Patel also possesses a wealth of experience in managerial roles. He has done a lot of work in addressing health inequalities, and notably, in 2020, he prescribed the very first COVID-19 vaccine.

Reacting to recommendations from a UK-first independent review, the Department of Health and Social Care (DHSC) has outlined action to tackle potential bias in the design and use of medical devices. Professor Dame Margaret Whitehead, professor of public health at the University of Liverpool, was appointed to lead the review, which focused on three areas - optical devices such as pulse oximeters, AI-enabled devices, and polygenic risk scores (PRS) in genomics. The DHSC commissioned the medical devices review after concerns were raised that pulse oximeters - widely used during the COVID-19 pandemic to monitor blood oxygen levels - were not as accurate for patients with darker skin tones. There were worries that this could cause delays in treatment if dangerously low oxygen levels in such patients were missed. However, no evidence was found from NHS studies indicating that this differing performance had an impact on patient care. Accepting the report's conclusions, the DHSC has committed to several actions, such as ensuring the safe use of pulse oximeter devices across a range of skin tones within the NHS and eliminating racial bias from data sets employed in clinical studies.

Navigating the complex world of medical insurance can often feel overwhelming, with a myriad of plans, coverage options, and terminologies to understand. However, being well-informed about medical insurance is crucial to making educated decisions that ensure you and your loved ones are adequately protected in times of health emergencies. This blog aims to demystify some of the essential aspects of medical insurance, providing you with 6 crucial pieces of information that everyone should know. Whether you're purchasing your first policy or looking to better understand your current plan, this guide is designed to empower you with the knowledge needed to make informed choices about your healthcare coverage. Expat Options For expatriates living and working away from their home countries, having reliable medical insurance is not just important-it's essential. Navigating healthcare systems in a foreign country can be daunting, and without proper coverage, the financial implications of medical emergencies can be severe. For example, in Dubai medical insurance for your wife's dependents is mandatory, and in the United States, medical bills can easily rack up into the thousands for even minor treatments. Therefore, expats should research their options carefully and ensure that they have comprehensive coverage that meets their specific needs.

British Pharma giant, GSK is planning to invest more than £200 million (about $253 million) into the United Kingdom over the next two years to strengthen its manufacturing network. The money will be used to improve the pharmaceutical group's UK sites, including construction of new facilities and assembly lines, The Daily Mail first reported on Sunday. GSK has already earmarked £67 million to upgrade its manufacturing site in Montrose, Scotland, where a new production facility is being constructed. The upgrade is expected to help boost its production of active pharmaceutical ingredients (API) for the future supply of medicines. Regis Simard, head of global supply chain, told the publication that their six UK manufacturing sites, including Montrose, are an important part of their global manufacturing network.

The Pharmacists' Defence Association (PDA) has submitted evidence to the NHS Pay Review Body (PRB), emphasising on the recruitment and retention of NHS pharmacists. It has urged the PRB to help the NHS achieve two important objectives - ensuring that pharmacists can achieve well-rewarded and the service is viewed as an a ppealing alternative by student pharmacists. The PDA suggested that for the NHS to remain competitive, the PRB should focus its pay approach on employees within Bands 5-8 this year. It recognised that the last recommendation from the PRB was a "flat rate increase" and it left those working in the above-mentioned bands feeling "unhappy", which led to the CSP taking strike action over pay for the first time in their history.

Pfizer on Thursday said a single dose of its new respiratory syncytial virus (RSV) vaccine Abrysvo maintained its ability to protect against the illness through a second year of respiratory disease season. The company said in a press release that the vaccine's efficacy against RSV-associated lower respiratory tract disease with three or more symptoms was 77.8 per cent through season two, compared with efficacy of 88.9 per cent after the first RSV season, which led to the shot's US approval. The data is from a late-stage trial of more than 37,000 participants being conducted in both the Northern and Southern hemispheres. Cumulative efficacy over both seasons after around 16.4 months of disease surveillance was 81.5 per cent, Pfizer said. The data is similar to the efficacy of GSK's rival RSV shot Arexvy over two seasons, which was released in June.

In a bid to address the ongoing deficit in staff in the UK's healthcare system, the National Health Service (NHS) has entered into a new workforce agreement with India. According to media reports, the healthcare service plans to hire 2,000 doctors from India on a fast-track basis to alleviate this pressing issue. It is learned that the NHS has set up training centres across many Indian cities such as Mumbai, Bangalore, Nagpur, Delhi, Gurugram, Indore, Mysore, Chennai, and Calicut to provide postgraduate training for the first batch of doctors. Post their training period (which ranges from six to 12 months), these doctors will be deployed at hospitals across Britain. They will also be exempted from the Professional and Linguistic Assessments Board (PLAB) examination that is otherwise mandatory for practising in the country.